Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of product sales | 3,840 | 2,798 | 9,217 | 7,366 |
| Acquired in-process research and development | — | — | 697,761 | — |
| Research and development | 51,969 | 43,386 | 112,288 | 80,656 |
| Selling, general and administrative | 63,976 | 87,383 | 158,530 | 169,852 |
| Total operating expenses | 119,785 | 133,567 | 977,796 | 257,874 |
| Income (loss) from operations | 98,465 | 29,786 | (603,133) | 51,013 |
| Other income (expense): | ||||
| Interest income | 2,434 | 2,516 | 4,690 | 5,540 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's SG&A?
- BioCryst Pharmaceuticals (BCRX) reported SG&A of $63.98M in Q2 2026.
- How has BioCryst Pharmaceuticals's SG&A changed year-over-year?
- BioCryst Pharmaceuticals's SG&A decreased by 26.8% year-over-year, from $87.38M to $63.98M.
- What is the long-term trend for BioCryst Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's SG&A has grown at a 30.9% compound annual growth rate (CAGR), from $118.82M to $348.65M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about BioCryst Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude